Drug resistance profile of Mycobacterium tuberculosis in China: update until 2024
Frontiers in Microbiology · 09.12.2025 · 16
DOI: 10.3389/fmicb.2025.1697490 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 09.12.2025. Verfasst von Yannan Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Shantou University, Shantou, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The situation of drug-resistant tuberculosis in China remains serious and complex. The majority of the study data are still derived from the 2,207 national survey of drug-resistant tuberculosis. In this study, we aimed to comprehensively characterize the prevalence of Mycobacterium tuberculosis (MTB) in China and update the catalogue of drug-resistant mutations while accounting for geographic variability. Materials and methods This study analyzed Mycobacterium tuberculosis ( M. tuberculosis ) isolates collected from 27 provinces, municipalities, and autonomous regions across China. All strains were analyzed for resistance to isoniazid, rifampicin, streptomycin, ethambutol, pyrazinamide, and quinolones based on the results of phenotypic drug sensitivity tests. The spatial and temporal distribution characteristics of drug-resistant strains were assessed based on the geographic origin and collection time of the isolates. The association between mutations and drug resistance was evaluated using mutation rates, positive predictive values, chi-square or Fisher’s exact test p -values, and 95% confidence intervals.
Results
55,388 MTB strains collected from 2002 to 2024 were analyzed, among which 15,078 were drug-resistant, including 7,848 multidrug-resistant strains. The resistance rates for INH, RFP, SM, EMB, PZA, and QS were 27.67, 25.33, 11.55, 6.19, 8.63, and 20.63%, respectively. Regional distribution patterns revealed that the eastern and western regions had the highest number of strains, but relatively low resistance rates. There was a low inflection point in 2019 for the resistance rates of all drugs except INH, whose resistance rate continued to increase after 2017. A total of 754 non-synonymous mutations were identified, with the highest mutation rates observed in INH (32.91%), RIF (28.98%), and QS (14.47%). The dominant mutation sites were katG (315AGC → ACC), rpoB (531TCG → TTG), and gyrA (94GAC → GGC), respectively. In addition, 96 newly detected mutations potentially associated with drug resistance were identified, including ahpC (11CCG → CCG) and pncA (226ACT → CCT). Combined mutations were most frequently observed in rpoB + rpoB , katG + katG , and katG + inhA , with other double-mutation combinations also being predominant.
Conclusion
Our analysis demonstrates that drug-resistant tuberculosis remains a serious challenge in China. Newly identified resistance-conferring mutations should be prioritized and integrated with the specific epidemiological characteristics of DR-TB in China to support the development and implementation of rapid diagnostic technologies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Public Health, Shantou University, Shantou, China.
- School of Basic Medicine and Public Health, Jinan University, Guangzhou, China.
- Shantou Tuberculosis Prevention and Control Institute, Shantou, China.
- State Key Laboratory for Zoonotic Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, Institute of Zoonosis, and College of Veterinary Medicine, Jilin University, Changchun, China.
Zitieren
APA
Xu, Y., Liu, S., Zheng, J., Lin, J., Gi, L., & Chang, Q. (2025). Drug resistance profile of Mycobacterium tuberculosis in China: update until 2024. Frontiers in Microbiology, 16. https://doi.org/10.3389/fmicb.2025.1697490
Vancouver
Xu Y, Liu S, Zheng J, Lin J, Gi L, Chang Q. Drug resistance profile of Mycobacterium tuberculosis in China: update until 2024. Frontiers in Microbiology. 2025;16. doi:10.3389/fmicb.2025.1697490
BibTeX
@article{Xu2025,
author = {Xu, Yannan and Liu, Sixuan and Zheng, Jiaxiong and Lin, Jianxiong and Gi, Liwei and Chang, Qiaocheng},
title = {Drug resistance profile of Mycobacterium tuberculosis in China: update until 2024},
journal = {Frontiers in Microbiology},
year = {2025},
volume = {16},
doi = {10.3389/fmicb.2025.1697490}
}
EUVIMED